Want to see HK:2496 full AI Analyst Report?
Wuhan YZY Biopharma Co., Ltd. Class H (2496) AI Stock Analysis
Wuhan YZY Biopharma Co., Ltd. Class H
(HKEX:2496)
Weak financial performance with negative equity and persistent losses is the dominant factor. Mixed technical signals and unfavorable valuation metrics due to negative earnings further limit the score.
Wuhan YZY Biopharma Co., Ltd. Class H (2496) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 678.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 208.75K
- Price to Earnings (P/E)
- -13.9
- Beta (1Y)
- 0.20
- Revenue Growth
- -55.22%
- EPS Growth
- 57.76%
- Country
- Hong Kong
- Employees
- 106
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Wuhan YZY Biopharma Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic condi...
Wuhan YZY Biopharma Co., Ltd. Class H Financial Statement Overview
Summary
Persistent losses with net margins at -126.7%, negative equity of -53.1 million, elevated debt, and ongoing cash burn signal high financial distress and insolvency risk.
Income Statement
15Very NegativeBalance Sheet
20Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 89.68M | 65.13M | 107.81M | 11.92M | 2.28M | 12.18M |
| Gross Profit | 34.53M | 6.17M | 85.07M | 11.92M | 2.28M | 12.18M |
| EBITDA | -39.37M | -83.49M | -86.95M | -157.46M | -168.63M | -124.61M |
| Net Income | -47.72M | -82.54M | -97.60M | -190.98M | -188.87M | -148.52M |
Balance Sheet | ||||||
| Total Assets | 177.01M | 175.08M | 267.84M | 301.62M | 302.84M | 200.16M |
| Cash, Cash Equivalents and Short-Term Investments | 75.98M | 100.11M | 126.28M | 196.68M | 200.52M | 83.71M |
| Total Debt | 138.62M | 127.81M | 127.35M | 90.11M | 76.67M | 28.48M |
| Total Liabilities | 235.55M | 228.13M | 237.31M | 173.97M | 146.96M | 56.99M |
| Stockholders Equity | -58.55M | -53.05M | 30.54M | 127.65M | 155.88M | 143.16M |
Cash Flow | ||||||
| Free Cash Flow | -86.76M | -22.46M | -102.22M | -187.95M | -156.40M | -82.10M |
| Operating Cash Flow | -80.39M | -21.57M | -100.72M | -186.02M | -155.16M | -80.55M |
| Investing Cash Flow | -6.25M | -130.00K | -4.67M | 54.81M | 5.80M | -19.93M |
| Financing Cash Flow | -33.03M | -4.68M | 33.02M | 176.29M | 241.33M | 81.03M |
Wuhan YZY Biopharma Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2496, the sentiment is Positive. The current price of 4.00 is above the 20-day moving average (MA) of 3.35, above the 50-day MA of 3.32, and below the 200-day MA of 4.70, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 72.43 is Negative, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2496.
Wuhan YZY Biopharma Co., Ltd. Class H Peers Comparison
Overall Rating
HK:218157Neutral
HK:124452Neutral- HK:249643Neutral
HK:213742Neutral
HK:289842Neutral
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2181 | 57Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| HK:1244 | 52Neutral | HKD 673.84M | -3.12 | -30.93% | ― | -17.22% | -6.13% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2496 | 43Neutral | HKD 1.05B | -13.87 | 85.52% | ― | -55.22% | 57.76% |
| HK:2137 | 42Neutral | HKD 708.65M | -3.48 | -7.32% | ― | ― | 51.71% |
| HK:2898 | 42Neutral | HKD 970.43M | -8.74 | -39.21% | ― | ― | ― |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2496 | Wuhan YZY Biopharma Co., Ltd. Class H | 4.00 | -3.01 | -42.94% | |
| HK:2137 | Brii Biosciences Limited | 0.98 | -0.91 | -48.15% | |
| HK:1244 | 3D Medicines, Inc. | 2.61 | -3.53 | -57.49% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:2898 | Sunho Biologics,Inc. | 6.39 | -1.61 | -20.13% |
Wuhan YZY Biopharma Co., Ltd. Class H Corporate Events
Wuhan YZY Biopharma Seeks Shareholder Nod for Insider Share Subscription and Whitewash Waiver
Wuhan YZY Biopharma has called an extraordinary general meeting for 17 November 2026 in Wuhan to seek shareholder approval for a major share subscription by three executive-linked subscribers, including chairman and CEO Dr. Zhou Pengfei, involving 35...
Wuhan YZY Biopharma Sets November EGM to Approve Capital and Governance Changes
Wuhan YZY Biopharma has scheduled an extraordinary general meeting for 17 November 2026 in Wuhan to consider matters including a share subscription, a specific mandate, a whitewash waiver and proposed amendments to its articles of association. The co...
YZY Biopharma Doses First Patient in Phase I Trial of Emicizumab Biosimilar Y225
Wuhan YZY Biopharma Co., Ltd., a Chinese biopharmaceutical company specializing in antibody drugs and biosimilars, is advancing therapies aimed at improving long-term care for chronic and rare diseases, including hemophilia A. Through proprietary for...
Wuhan YZY Biopharma Seeks Extension for Key Share Subscription Circular
Wuhan YZY Biopharma Co., Ltd. has announced a delay in sending a circular to shareholders regarding a proposed connected share subscription, a specific mandate for issuing new domestic shares, a whitewash waiver, and amendments to its articles of ass...
Wuhan YZY Biopharma Reshapes Company Secretary and Process Agent Roles
Wuhan YZY Biopharma announced that the Hong Kong Stock Exchange has confirmed current joint company secretary Mr. Zheng Jianhua is qualified to serve as the company secretary once a prior waiver expires on September 24, 2026. As a result, joint compa...
Wuhan YZY Biopharma Plans Major Connected Share Issue Requiring Whitewash Waiver
Wuhan YZY Biopharma plans to issue 35,592,400 new domestic shares at RMB2.43 per share under a specific mandate, raising estimated net proceeds of about RMB83 million. The new shares represent roughly 247.68% of existing domestic shares and will sign...
Wuhan YZY Biopharma Halts Hong Kong Trading Ahead of Takeover-Related Announcement
Wuhan YZY Biopharma Co., Ltd. has requested a halt in trading of its shares on the Hong Kong Stock Exchange, effective from 9:00 a.m. on 31 August 2026. The suspension precedes the release of an announcement under Hong Kong’s Codes on Takeovers...
Wuhan YZY Biopharma Narrows Interim Loss but Net Liabilities Deepen
Wuhan YZY Biopharma reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB33.1 million, down from RMB37.2 million a year earlier, but a sharp improvement in gross profit to RMB25.3 million from RMB7.7 millio...
Wuhan YZY Biopharma Sets Board Meeting to Approve Interim 2026 Results
Wuhan YZY Biopharma Co., Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The meeting will also address other corporate matte...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026